Inflammatix secures $102 million in new financing to help commercialize its point-of-care diagnostics portfolio aimed at profiling a person's immune response to quickly ascertain bacterial and viral infections and help curb potential antimicrobial resistance.
Find more companies like Inflammatix
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.